Recently, a study on the positive benefits of elevated parathyroid hormone (PTH) caused by denosumab therapy was conducted by researchers from the National Taiwan University Hospital. The study concluded that elevated PTH induced by denosumab increases bone mineral density and reduces bone turnover in postmenopausal women.

The study included 24 postmenopausal women with osteoporosis who were treated with denosumab for six months. During the study period, all of the participants had a serum PTH level at least twice the upper limit of the normal reference range. After six months, the researchers found that the elevated PTH level caused by denosumab therapy resulted in increased bone mineral density in the lumbar spine and femoral neck, as well as reduced bone turnover, which was measured by reduced serum type-I-collagen C terminus levels.

The study concluded that denosumab-induced elevated PTH has beneficial effects on bone health. Elevated PTH increases bone mineral density and reduces bone turnover, which may reduce the risk of bone fractures and other bone-related damage. Additionally, PTH appears to also stimulate other bone-protective factors as well, such as stimulating the production of vitamin D and promoting calcium absorption from the gut.

The results of this study may have important implications for clinical practice. Denosumab is already used clinically to treat postmenopausal women with osteoporosis, and the findings suggest that the elevation of PTH it induces may confer additional benefits beyond the direct effects of the drug. Further research is needed to confirm these benefits and to determine the best way to maximize the beneficial effects of denosumab therapy.